Legend Biotech

Legend Biotech Debt/EBITDA

The Total Debt to EBITDA Ratio of Legend Biotech (LEGN) as of Nov 22, 2026 is -3.03. In the previous year, Total Debt to EBITDA Ratio was -1.16 — a change of 162.14% (lower).

Debt/EBITDA

-3.03

YoY

162.14%

Last updated:

Total Debt to EBITDA Ratio of Legend Biotech is 2025 -3.03 . Total Debt to EBITDA Ratio of Legend Biotech was 2024 -1.16 . It decreases by 162.14% lower compared to the previous year.

The Legend Biotech Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-2.81 USD
Jan 1, 2019
-0.05 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.31 USD
Jan 1, 2022
-0.62 USD
Jan 1, 2023
-0.75 USD
Jan 1, 2024
-1.16 USD
Jan 1, 2025
-3.03 USD
The Legend Biotech Debt/EBITDA history
YEARDebt/EBITDAYoY
-3.03+162.14%
-1.16+54.60%
-0.75+19.75%
-0.62+99.23%
-0.31+2,554.63%
-0.01-74.40%
-0.05-98.36%
-2.81-14,517.34%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Legend Biotech Stock analysis

What does Legend Biotech do? Legend Biotech Corp is a leading biopharmaceutical company specializing in the discovery and development of innovative cell therapies for the treatment of serious diseases such as cancer. The company was founded in 2015 as a subsidiary of Genscript Biotech Corp and is headquartered in Somerset, New Jersey, USA. Additionally, the company also operates locations in China and Europe. Legend Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Legend Biotech stock

Total Debt to EBITDA Ratio of Legend Biotech is -3.03 in 2025.

Total Debt to EBITDA Ratio of Legend Biotech changed from -1.16 to -3.03, representing a 162.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Legend Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Legend Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Legend Biotech

All Key Metrics — Legend Biotech